4-13-06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

cation No.:

10/532,452

Filed:

04/22/2005

1st Inventor:

Y. Shimomura

For:

Antibody and Utilization of the Same

Atty. Dkt. No.

3104US0P

Art Unit:

1614

tba

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. 684084012 US

DATE IN:

February 10, 2006

Itemized Papers/Items:

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Form (1 page X 2)
- 3. Supplemental Information Disclosure Statement (1 page) with Form PTO/SB/08B(1 page), and cited references (3)
- 4. Supplementary Partial European Search Report (4 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

> Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

on this date, February 10, 2006

Dated: 2/10/06

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

FEB 1 0 2006 Page

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/532,452 TRANSMITTAL Filing Date 04/22/2005 First Named Inventor **FORM** Y. Shimomura Art Unit 1614 **Examiner Name** tha (to be used for all correspondence after initial filing) Attorney Docket Number 3104US0P Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a **Proprietary Information** After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer** Extension of Time Request below): Return Postcard; Request for Refund **Express Abandonment Request** Certificate of Express Mailing; Form PTO SB/08B CD, Number of CD(s) Information Disclosure Statement Cited references (3) Landscape Table on CD Certified Copy of Priority Remarks Document(s) The Commissioner is hereby authorized to charge any additional fees which may be required, Reply to Missing Parts/ or credit any overpayment to Deposit Account 500799. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Mark Chao, Ph.D., JD Date Reg. No. 37,293 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail # EV 684084012

Gail L. Winokur

Typed or printed name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/532,452

Filed:

04/22/2005

1st Inventor:

Y. Shimomura

For:

Antibody and Utilization of the Same

Atty. Dkt. No.

3104US0P

Art Unit:

1614

Examiner:

ιυ

Allowed:

Batch:

Paper No.:

Supplemental Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached Form PTO/SB/08B A legible copy of each listed reference is herewith being provided to the Examiner.

This reference was cited in European Search Report dated December 28, 2005 issued in the foreign application corresponding to the above-identified application. No fee is required for this filing.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfullysut

Dated:

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA Underline Rappers

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10k/532,452	
INFORMATION DISCLOSURE	Filing Date	04/22/2005	
STATEMENT BY APPLICANT	First Named Inventor	Y. Shimomura	
(Use as many sheets as necessary)	Art Unit	1614	
(Use as many sneets as necessary)	Examiner Name	tba	
Sheet 1 of 1	Attorney Docket Number	3104US0P	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	D. MC MASTER, et al., "Characterization of the Biologically and Antigenically Important Regions of Urotensin II", Proc. West. Pharmacol. Soc., 29: 205-208(1986)	
	B2	S.A. DOUGLAS, et al., "Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified To Date, as a Therapeutic Target for the Management of Cardiovascular Disease", TCM, 10(6): 229-237(2000)	
	В3	F.D. RUSSELL, et al., "Elevated Plasma Levels of Human Urotensin-II Immunoreactivity in Congestive Heart Failure", Am. J. Physiol. Heart Cir. Physiol., 285: H1576-H1581(2003)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.